Asosiy kontentga oʻtish
Maqola

<sup>68</sup>Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer

Clemens KratochwilDepartment of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany [email protected]Paul FlechsigDepartment of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, GermanyThomas LindnerUniversity Hospital HeidelbergLabidi AbderrahimDepartment of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, GermanyAnnette AltmannDepartment of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, GermanyWalter MierUniversity Hospital HeidelbergSebastian AdebergHeidelberger Institut für RadioonkologieHendrik RathkeDepartment of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, GermanyManuel RöhrichDepartment of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, GermanyH. WinterDepartment of Surgery, Thoraxklinik at University Hospital Heidelberg, Heidelberg, GermanyPeter K. PlinkertUniversity Hospital HeidelbergFrederik MarméUniversity Medical Centre MannheimMatthias LangUniversity Hospital HeidelbergHans‐Ulrich KauczorTranslational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, GermanyDirk JägerDepartment of Medical Oncology and Internal Medicine VI, National Center for Tumor Diseases, University Hospital Heidelberg, GermanyJürgen DebusHeidelberger Institut für RadioonkologieUwe HaberkornGerman Center for Lung ResearchFrederik L. GieselUniversity Hospital Heidelberg
2019en
ABI

Annotatsiya

The recent development of quinoline-based PET tracers that act as fibroblast-activation-protein inhibitors (FAPIs) demonstrated promising preclinical and clinical results. FAP is overexpressed by cancer-associated fibroblasts of several tumor entities. Here, we quantify the tumor uptake on <sup>68</sup>Ga-FAPI PET/CT of various primary and metastatic tumors to identify the most promising indications for future application. <b>Methods:</b><sup>68</sup>Ga-FAPI PET/CT scans were requested by various referring physicians according to individual clinical indications that were considered insufficiently covered by <sup>18</sup>F-FDG PET/CT or other imaging modalities. All PET/CT was performed 1 h after injection of 122–312 MBq of <sup>68</sup>Ga-FAPI-04. We retrospectively identified 80 patients with histopathologically proven primary tumors or metastases or radiologically unequivocal metastatic lesions of histologically proven primary tumors. Tumor uptake was quantified by SUV<sub>max</sub> and SUV<sub>mean</sub> (60% isocontour). <b>Results:</b> Eighty patients with 28 different tumor entities (54 primary tumors and 229 metastases) were evaluated. The highest average SUV<sub>max</sub> (&gt;12) was found in sarcoma, esophageal, breast, cholangiocarcinoma, and lung cancer. The lowest <sup>68</sup>Ga-FAPI uptake (average SUV<sub>max</sub> &lt; 6) was observed in pheochromocytoma, renal cell, differentiated thyroid, adenoid cystic, and gastric cancer. The average SUV<sub>max</sub> of hepatocellular, colorectal, head–neck, ovarian, pancreatic, and prostate cancer was intermediate (SUV 6–12). SUV varied across and within all tumor entities. Because of low background in muscle and blood pool (SUV<sub>max</sub> &lt; 2), the tumor-to-background contrast ratios were more than 3-fold in the intermediate and more than 6-fold in the high-intensity uptake group. <b>Conclusion:</b> Several highly prevalent cancers presented with remarkably high uptake and image contrast on <sup>68</sup>Ga-FAPI PET/CT. The high and rather selective tumor uptake may open up new applications for noninvasive tumor characterization, staging examinations, or radioligand therapy.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar

3 ta iqtibos0 ta foydalanilgan manba